Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modafinil for cognitive impairment in remitted depression
NCT03620253Phase 3Terminated
- Sponsor
- Unity Health Toronto
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of modafinil in major depressive disorder (MDD), sponsored by Unity Health Toronto. Started Oct 2018; status: terminated.
02
Drugs
modafinil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03620253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620253.